Dr. Davey B. Daniel, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 685
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Johns Hopkins University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license MD39892 · GA license 056539
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Parkridge Medical Center Chattanooga, TN
- Hamilton Medical Center Dalton, GA
- Commonspirit-Memorial Hospital-North Georgia Ringgold, GA
Medical groups
- Tennessee Oncology PLLC (358 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 685
- Services billed
- 150,372
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 27,000 | 21 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 26,250 | 208 |
| Injection, pembrolizumab, 1 mg | 12,400 | 15 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,552 | 350 |
| Insertion of needle into vein for collection of blood sample | 1,423 | 357 |
| Blood test, comprehensive group of blood chemicals | 1,369 | 341 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,074 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 526 | 294 |
| Established patient office or other outpatient visit, 40-54 minutes | 420 | 122 |
| Administration of chemotherapy into vein, 1 hour or less | 303 | 95 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Chattanooga, TN | 140 |
| Abiraterone Acetate | 99 |
| Anastrozole Other prescribers in Chattanooga, TN | 74 |
| Eliquis (apixaban) Other prescribers in Chattanooga, TN | 70 |
| Mirtazapine Other prescribers in Chattanooga, TN | 59 |
| Ondansetron Odt (ondansetron) Other prescribers in Chattanooga, TN | 51 |
| Prochlorperazine Maleate Other prescribers in Chattanooga, TN | 45 |
| Letrozole Other prescribers in Chattanooga, TN | 37 |
| Dexamethasone Other prescribers in Chattanooga, TN | 35 |
| Pantoprazole Sodium Other prescribers in Chattanooga, TN | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 20 payments worth $1,485 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $337 |
|---|---|
| Pfizer Inc. | $208 |
| Asd Specialty Healthcare, LLC | $194 |
| Genentech USA, Inc. | $166 |
| Janssen Scientific Affairs, LLC | $141 |
| Amgen Inc. | $128 |
| Kite Pharma, Inc. | $111 |
| Novartis Pharmaceuticals Corporation | $70.74 |
| Food and Beverage | $1,397 |
|---|---|
| Education | $87.80 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
| Novartis Pharmaceuticals Corporation Apr 9, 2025 | Education PLUVICTO · Oncology · in-kind | $19.31 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $233,039 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 Open label Dose escalation and Dose expansion study to evaluate the safety to evaluate the safety tolerability Pharmacokinetics Immunogenicity and Antitumor activity of MEDI5752 in subjects with advanced sol…
AstraZeneca UK Limited - Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC
Genentech, Inc. - PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC
Genentech, Inc. - Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06
Genentech, Inc. - 1LM SCLC Tecentriq Lurbinectedin
Genentech, Inc. - A phase 2 openlabel study of encorafenib binimetinib in patients with BRAFV600MUTANT nonsmall cell lung cancer
Array Biopharma Inc - Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)
AstraZeneca UK Limited - A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Canc…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.